Te­va and Alvotech's in­ter­change­able Hu­mi­ra biosim­i­lar joins the par­ty

No more wait­ing in the wings. Te­va and Alvotech won ap­proval Fri­day for their Hu­mi­ra biosim­i­lar Sim­lan­di af­ter re­solv­ing man­u­fac­tur­ing is­sues that caused mul­ti­ple re­jec­tions.

The part­ners will launch their in­ter­change­able, high-con­cen­tra­tion Sim­lan­di “im­mi­nent­ly,” they said in a news re­lease. The drug will be up against sev­er­al oth­er biosim­i­lars al­ready on the mar­ket, but Te­va’s CEO Richard Fran­cis isn’t wor­ried about be­ing late to the par­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER